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1751-31 Lovastatin and Probucol for the Prevention of
Restenosls After Coronary Angioplasty
groups in baseline clinical characteristics. The acute gain (0.96 ± 0.42 mm,
1.03 ± 0.40 mm) and late loss (0.36 ± 0.51 mm, 0.36 ± 0.57 mm) were
similar in the Fraxiparine and aspirin groups. Restenosis, defined as a binary
variable (stenosis >50% at angiographic follow-up) occurred in 41 % of the
Fraxiparine treated and 38% of the aspirin treated group (p = 0.69). At six
months major clinical event rates, death (1 % vs 2%), acute myocardial in-
farction (4% vs 2%1 and repeat revascularization 126% vs 26%) were similar
in both groups.
Despite, 3 days of pretreatment and 3 months of treatment with low
molecular weight heparin (Fraxiparine), no statistical differences were ob-
served in angiographic or clinical end points.
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Rapid Angiographlc Progression of "Target" and
"Non-target" Stenoses in Patients Awaiting Coronary
Angioplasty
Juan Carlos Kaski, Lilia Chen, Michael Chester. St. George's Hospital Medical School,
London, U.K.
Coronary angioplasty (PTCA) is effective therapy for angina pectoris but coro-
nary events occur after successful PTCA which may be caused by both
restenosis and progression of mild pre-existing, "non-target", stenoses. To
compare the short-term evolution of "target" versus "non-target" stenoses
in patients awaiting PTCA, we prospectively studied 161 consecutive sta-
ble angina patients (124 men and 37 women). After diagnostic angiography,
"target" stenoses for PTCA and "non-target" lesions were identified. Patients
were put on a routine waiting list and followed up regularly until repeat coro-
nary arteriography (mean ± SD: 7 ± 3 months). which was performed im-
mediately preceding angioplasty (138 patients) or soon after acute coronary
events (23 patients) when these occurred. Stenosis diameters were mea-
sured using computerized arteriography. Progression was defined as 2:20%
diameter reduction, new total occlusion, or development of "new" stenoses
2:30%. At study entry, diameters of target (n = 207) and non-target (n = 184)
lesions were 68 ± 9% and 38 ± 9%, respectively (p < 0.001). Disease pro-
gression occurred in 33 patients (20%). in whom 18 target (9%) and 15 non-
target stenoses (8%) progressed and 7 new lesions (1 total occlusion) devel-
oped. Total occlusion developed in 15 of the 18183%) target and in 6 of the
15 (40%) non-target stenoses; (p = 0.03). During follow up, 3 patients (2%)
had a myocardial infarction and 20 (12%) developed unstable angina. These
events were associated with progression of target stenoses in 10 patients,
of non-target stenoses in 7 patients, and with new lesions in one patient. In
5 patients events were not associated with stenosis progression.
Thus a similar proportion of target and non-target lesions progressed
rapidly. Target stenoses, however, were more likely to progress to total oc-
clusion than non-target lesions. Progression of non-target stenoses may con-
tribute to recurrence of angina and new coronary events after successful
angioplasty and their role should be considered when developing strategies
aimed at improving survival after angioplasty.
1751-61 Multiple Repeat Coronary Angioplasty for Final
Lesion Patency
Hidemasa Kitazume, Ichiro Kubo, Yoshio Ageishi, Toru Iwama, Akio Suzuki. Bokuto
Hospital, Tokyo, Japan
To demonstrate that multiple repeat coronary angioplasty can be solely uti-
lized to achieve final lesion patency after restenosis, such a protocol was
prospectively applied for restenosis since 1983. Bypass surgery was only
considered for 1) new left main trunk lesions, 21 symptomatic restenosis
where angioplasty was either unsuccessful or unsuitable, and 3) patient
preference. Between 1983 and 1992, 1455 lesions (acute myocardial infarc-
tion or total occlusion excluded) were successfully dilated for the first time.
Although only 941 (68%) of the 1385 lesions studied showed satisfactory
patency (:::70% stenosis) after the first procedure, 93% (1248/1345 stud-
ied) showed satisfactory patency after repeating angioplasty up to 3 times
and 94% (1268/1354 studied) after repetition up to 6 times. Only 23 lesions
11.6%) required 4 or more procedures and 20 of them showed final patency.
Disease aggravation (either impossible or failed repeat angioplasty, acute in-
farction, or sudden death) occurred in 43 lesions (3.2%). Bypass grafts were
done for 11 lesions of 7 patients, mostly due to disease progression at the
left main trunk.
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Patricia G. Cavera, James H. O'Keefe, Jr., Gregg W. Stone, Ben D. McCallister, Jr.,
Cheryl Dreiling, Robert Ligon, Ray L. Kacich. Mid America Heart Institute, Kansas City,
MO
We hypothesized that combination lipid lowering therapy (Lovastatin) and
anti-oxidant (Probucol) therapy might reduce restenosis following coronary
angioplasty(pTCAI. To address this question, 239 patients (pts) were enrolled
in a multi-center, randomized trial whereby 2 out of 3 pts received Lovas-
tatin 20 mg bid and Probucol 500 mg bid in combination; lout of 3 pts was
randomized to double placebo. Pts were treated in a blinded fashion for 6
months. Total cholesterol (154 vs 211), LDL 198 vs 141) and HDL (31 vs 42)
were lower in treated compared with placebo patients. Serious adverse ef-
fects from the medications were not observed.
EVENTS WITHIN 6 MONTHS
Quantitative coronary angiography was available in 147 lesions, the mean
loss in luminal diameter was 27% ± 31 % and 28% ± 34% in treated and
placebo groups.
Conclusion: Combination Lovastatin and Probucol: 1) reduced total choles-
terol (27%). LDL (29%) and HDL (27%) levels, but 2) did not prevent resteno-
sis or clinical events during the first six months post-angioplasty.
(PTCA). Reducing platelet accumulation at PTCA sites may attenuate NP
and restenosis. Single antiplatelet agents are not effective, due to multiple
platelet activation pathways. Previous work suggested that combined antag-
onism of 2 mediators of platelet aggregation -thromboxane A2 (byridogre/)
and serotonin (by kemnserin). could reduce platelet-thrombus formation and
lessen NP We therefore tested the hypothesis that combined treatment with
3 agents (ridogrel, kemnserin. and an ADP antagonist - clopidogre/l would
be more effective in reducing NP after PTCA. We studied 18 dogs with coro-
nary flow probes and plastic constrictors chronically implanted on LAD arter-
ies. All dogs underwent LAD PTCA and were sacrificed after 8 weeks of mon-
itoring. Eight dogs were controls, while 10 dogs were treated with combined
anti platelet therapy for 3 weeks before and 3 weeks after PTCA. Compared to
controls, ex vivo platelet aggregation was virtually abolished in treated dogs,
and bleeding times during treatment were greater (>720 vs 119 ± 4 sec, p <
0.001). Cyclic flow variations (CFVs) after PTCA, from repetitive accumulation
and dislodgement of platelet aggregates at PTCA sites, occurred in 7/8 con-
trols but in only 1/10 treated dogs (p < 0.01). Platelet counts and hematocrit
values were not different between treated and control groups. Quantitative
coronary artery histology revealed that neointimal area was threefold less in
the treated group (0.18 ± 0.07 cm2 vs 0.52 ± 0.12, P = 0.032), as was the
percent lumen stenosis (13 ± 4% vs 40 ± 13%, P = 0.06).
Conclusion: Combination antiplatelet therapy with these 3 antagonists in-
hibited several relevant measures of platelet function and reduced neointi-
mal proliferation in a canine coronary artery angioplasty model.
Jean-Marc Lablanche, The FACT investigators. France, Belgium, Spain
Restenosis after coronary angioplasty is a multifactorial process that may
involve elastic recoil, thrombus incorporation, smooth muscle cell prolifera-
tion, and late vascular remodeling. Fraxiparine (nadroparin) is a low molecular
weight heparin derivative that has potent antithrombotic and antiproliferative
properties in animal models.
The FACT (Fraxiparine Angioplastie Coronaire Transluminale) study is a
multicentre double-blind randomised trial designed to compare the effects
of treatment with Fraxiparine or aspirin on the occurrence of restenosis af-
ter coronary balloon angioplasty. All patients received aspirin (250 mg, daily)
before coronary angioplasty. Therapeutic doses of unfractionated heparin
were used during coronary angioplasty in both groups. The active treatment
group received subcutaneous injections of Fraxiparine (0.6 ml) daily for 3
days before coronary angioplasty that was continued for 3 months. The con-
trol group was treated with aspirin (250 mg) daily for 3 months.
In total, 354 patients were randomized and constitute the intention-to-treat
population. Angiographic follow-up was performed in 91 % of patients with
successful procedures at 3 months. There were no differences between
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1751-41 Low Molecular Weight Heparin in the Prevention of
Restenosis After Coronary Angioplasty. Results of
the FACT Study
